Mark Sullivan, JD

Chief Legal Officer and Corporate Secretary

Mr. Sullivan is an experienced public company General Counsel and Corporate Secretary, with extensive expertise and demonstrated success in the areas of SEC reporting, financing, corporate governance and compliance, mergers and acquisitions, intellectual property, litigation management and business development. Prior to joining the Company, Mr. Sullivan was the General Counsel and Corporate Secretary of Sesen Bio, a biopharmaceutical company (prior to its merger with Carisma Therapeutics) (NASDAQ: CARM), from August 2019 to April 2023. Before that, he served as a private consultant to numerous life sciences companies. Previously, he served as the General Counsel, Chief Compliance Officer and Secretary of MModal Inc. (Nasdaq: MODL), formerly MedQuist, Inc., a leading healthcare IT company, until it was taken private by One Equity Partners, the private investment arm of JP Morgan Chase & Co. Prior to joining MModal, Mr. Sullivan was in private practice with Pepper Hamilton LLP and Drinker Biddle & Reath LLP. Mr. Sullivan received a B.A. from the University of Pennsylvania and a J.D. from the Rutgers University School of Law.

Carol Vallone

Chair of the Board of Directors, Chair of Compensation Committee, Member of Audit/Finance Committee

Andreas Krebs

Vice Chair of the Board of Directors, Chair of Nomination and Governance Committee, Member of Audit/Finance Committee

David Gryska

Board Director, Chair of Audit Committee

Roger Crystal, MD

Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee

Robert Barrow

Chief Executive Officer and Board Director

Suzanne Bruhn, PhD

Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee

Schond Greenway, MBA

Chief Financial Officer

Miri Halperin Wernli, PhD

Executive President

Daniel Karlin, MD, MA

Chief Medical Officer

Mark Sullivan, JD

Chief Legal Officer and Corporate Secretary

Francois Lilienthal, MD, MBA

Chief Commercial Officer

Carrie Liao, CPA

Chief Accounting Officer

Bridget Walton, MS

VP, Global Regulatory Affairs

Robert Malenka, MD, PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Carole Abel, MBA

VP, Programs and Portfolio Office (PPO)

Peter Mack, PhD

VP, Pharmaceutical Development

Rafael Muniz, MD

VP, Global Medical Affairs

Phong Duong, PharmD

VP, Global Market Access

Maria Oquendo, MD, PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Matthias Liechti, MD, PhD

Scientific Collaborator & Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Peter Gasser, MD

Clinical Advisor